C1(P(C2CCCCC2)C2C=CC=CC=2C2C=CC=CC=2N(C)C)CCCCC1.[CH:29]([N:32]1[CH2:37][CH2:36][N:35]([C:38]([CH:40]2[CH2:45][CH2:44][NH:43][CH2:42][CH2:41]2)=[O:39])[CH2:34][C@@H:33]1[CH3:46])([CH3:31])[CH3:30].Br[C:48]1[CH:49]=[N:50][C:51]([C:54]([F:57])([F:56])[F:55])=[N:52][CH:53]=1.CC(C)([O-])C.[Na+].[ClH:64]>O1CCOCC1.CO.C(Cl)Cl.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[ClH:64].[CH:29]([N:32]1[CH2:37][CH2:36][N:35]([C:38]([CH:40]2[CH2:41][CH2:42][N:43]([C:48]3[CH:49]=[N:50][C:51]([C:54]([F:57])([F:56])[F:55])=[N:52][CH:53]=3)[CH2:44][CH2:45]2)=[O:39])[CH2:34][C@@H:33]1[CH3:46])([CH3:31])[CH3:30]Tris(dibenzylideneacetone)dipalladium(0)(30 mg) and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (60 mg) were added to a solution of (S)-1-isopropyl4-(piperidine-4-carbonyl]-2-methyl piperazine (free base compound from D29)(0.134 g) and 5-bromo-2-trifluromethylpyrimidine (D30)(0.12 g) in degassed dioxane (3 ml). This was followed by the addition of sodium-t-butoxide (0.1 g). The reaction was carried out in a Personal Chemistry microwave reactor at 120° C. for 5 min. After cooling the reaction mixture was diluted with methanol (10 ml), the solids were filtered off and the filtrate was applied to an SCX resin column. Initial elution with methanol was followed by elubon with methanolic ammonia (2M). The ammoniacal eluates were concentrated to a gum and further purified by silica gel chromatography, eluting with 0-10% methanolic ammonia (2M) in DCM. Evaporation of the appropriate fractions gave the free base which was dissolved in DCM (3 ml) and treated with ethereal 1M HCl (2 ml) to give the title compound (E89) as a light yellow solid (56 mg). MS electrospray (+ve) 400 (MH+). 1H NMR δ [MeOH-d4]: 1.28-1.29 (3H, m), 1.4-1.5 (8H, m), 1.8-1.9 (4H, m), 2.98-3.2 (3H, m), 3.45-3.57 (3H, m), 4.0-4.08 (3H, m), 4.35-4.45 (1H, m), 4.6-4.78 (1H, s), 8.5 (2H, s).
Wird geladen…